Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 6, 2012, Pages 672-677

  Park, Youngjin ^a   Moriyama, Ayako ^a   Kitahara, Tomoaki ^a   Yoshida, Yutaka ^a   Urita, Tasuku ^a   Kato, Ryoji ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

BRCA; Breast cancer; DNA base excision repair; PARP; PARP inhibitors; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPETITIVE INHIBITION; GENE MUTATION; GENETIC SCREENING; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84861676580     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617759     Document Type: Review

References (40)

1. Sørlie, T.; Perou, C.M.; Tibshiranie, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; Matt van de Rijn; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein. D.; Lønning, P. E.; Børresen-Dale, A. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A, 2001, 98(19), 10869-10874.
2. Perou, C. M.; Sørlie, T.; Eisen, M. B.; Matt van de Rijn; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, Ø.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A.; Brown, P. O.; Botstein, D. Molecular portraits of human breast tumors. Nature, 2000, 406, 747-752.
3. Sørlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H., Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U S A, 2003, 100(14), 8418-8423.
4. Carey, L. A.; Perou, C. M.; Livasy, C. A.; Dressler, L. G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, J.; Cheang, M. C. U.; Nielsen, T. O.; Moorman, P. G.; Earp, H. S.; Millikan, R. C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21), 2492-2502.
5. Dent, R.; Hanna, W. M.; Trudeau, M.; Rawlinson, E.; Sun, P.; Narod, S. A. Pattern of metastatic spread in triple-negative breast cancer. Breast. Cancer. Res. Treat., 2009, 115, 423-428.
6. Marīa, S.; Pinilla, R.; Sarriō, D.; Honrado, E.; Hardisson, D.; Calero, F.; Benitez, J.; Palacios, J. Prognostic significance of basallike phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer. Res., 2006, 12(5), 1533-1539.
7. Plauletti, G.; Godolphin, W.; Press, M. F.; Slamon, D. J. Detection and quantitation od HER-2/neu gene amplicatioin in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996, 13(1), 63-72.
8. Nielsen, T. O.; Hsu, F. D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L. A.; Ragaz, J.; Gown, A. M.; Gilks, C. B.; Matt van de Rijn; Perou, C. M. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clin. Cancer. Res., 2004, 10(16), 5367-5374.
9. Rakha, E. A.; Tan, D. S.; Foulkes, W. D.; Ellis, L. O.; Tutt, A.; Nielsen, T. O.; Reis-Filho, J. S. Are triple-negative tumors and basal-like breast cancer synonymous?, Breast cancer research, 2007, 9, 404.
10. Beslija, S.; Bonneterre, J.; Burstein, H. J.; Cocquyt, V., Gnant, M.; Heinemann, V.; Jassem, J.; Köstler, WJ.; Krainer, M.; Menard, S.; Petit, T.; Petruzelka, L.; Possinger, K.; Schmid, P.; Stadtmauer, E.; Stockler, M.; Belle, S. V.; Vogel, C.; Wilcken., N.; Wiltschke, C.; Zielinski, C. C.; Zwierzina, H. for the Central European Cooperative Oncology Group (CECOG). Third consensus on medical treatment of metastatic breast cancer. Ann. Oncol., 2009, 20, 1771-1785.
11. Rouzier, R., Perou, C. M.; Symmans, W. F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K. R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, C. F.; Rabiul, I.; Ross, J. S.; Hortobagyi, G. N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res., 2005, 11(16), 5678-5685.
12. Liedtke, C.; Mazouni C.; Hess, K. R.; André, F.; Tordai, A.; Meija, J. A.; Symmans, W. F.; Gonzalez-Angulo, A. M.; Hennessy, B.; Cristofanilli, M.; Hortobagyi, G. H.; Pusztai, L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cnacer. J. Clin. Oncol., 2008, 26(8), 1275-1281.
13. Carey, L. A.; Dees, E. C.; Sawyer, L.; Gatti, L.; Moore, D. T.; Collichio, F.; Ollila, D. W.; Sartor, C. I.; Graham, M. L.; Perou, C. M. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin. Cancer Res., 2007, 13(8), 2329-2334.
14. Hoeijmakers, J. H. J. Genome maintenance mechanisms for preventing cancer. Nature, 2001, 411, 366-374.
15. Kinsella, T. J. Understanding DNA Damage Response and DNA Repair Rathways: Applications to More Targeted Cancer Therapeutics. Semin. Oncol., 2009, 36(1), 42-51.
16. D'Andrea, A. D.; Grompe, M. The Fanconi anaemia/BRCA pathway. Nature Reviews, 2003, 3, 23-24.
17. Tutt, A.; Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in Molecular Medicine, 2002, 8(12), 571-576.
18. Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol., 2007, 25(11), 1329-1333.
19. Pal, S. K.; Mortimer, J. Triple-negative breast cancer: Novel therapies and new directions. Maturitas, 2009, 63, 269-274.
20. Turner, N. C.; Reis-Filho, J. S. Basal-like breast cancer and the BRCA1 phenotypes. Oncogene, 2006, 25, 5846-5853.
21. Atchley, D. P.; Albarracin, C. T.; Lopez, A.; Valero, V.; Amos, C. I., Gonzalez-Angulo, A. M.; Hortobagyi, G. N.; Arun, B. K. Clinical and pathologic Characteristics of patients with BRCApositive and BRCA-negative breast cancer. J. Clin. Oncol., 2008, 26(26), 4282-4288.
22. Bartsch, R.; Ziebermayr, R.; Zielinski, C. C.; Steger, G. G. Triplenegative breast cancer. Wien Med Wochenschr, 2010, 160(7-8), 174-181.
23. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews, 2004, 4, 1-6.
24. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N. J.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I., Knights, C.; Martin, N. B. M.; Jackson, S. P.; Smith, G. C. M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917-921
25. Lindahl, T.; Satoh, M. S.; Poirier, G. G.; Klungland, A. Posttranslational modification of poly (ADPribose) polymerase induced by DNA strand breaks. Trends. Biochem. Sci., 1995, 20, 405-411.
26. D'Amours, D.; Desnoyers, S.; D'Silva, I.; Poirier, G. G. Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J., 1999, 243, 249-268.
27. EL-Khamisy, S. F.; Masutani, M.; Suzuki, H.; Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic. Acids. Res., 2003, 31(19), 5521-5533.
28. Schneider, B. P.; Winer, E. P.; Foulkes, W.; D.; Garber, J.; Perou, C. M.; Richardson, A.; Sledge, G. W.; Carey, L. A. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer. Res., 2008, 14(24), 8010-8018.
29. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirei, G. G. PARP inhibition: PARP1 and beyond. Nature, 2010, 10, 293-301.
30. Miwa, M.; Masutani, M. PolyADP-ribosylation and cancer. Cancer, Sci., 2007, 98(10), 1528-1535.
31. Glendenning, J.; Tutt, A. PARP inhibitors-current status and the walk towards early breast cancer. Breast, 20, 12-19.
32. Donawho, C. K.; Luo, Y.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S. Grimm, D. R. Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C., Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13(9), 2728-2738.
33. O'Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, C. K.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011, 364(3), 205-214.
34. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H. M.; de Bono, J. S. Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
35. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J, N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral Poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 2010, 376(24), 235-244.
36. Edwards, S. L.; Brough, R,.; Lord, C. J., Natrajan, R.; Vatcheva, R.; Levine, D. A.; Boyd, J.; Reis-Filho, J. S.; Ashworth, A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008, 451, 1111-1115.
37. Sakai, W.; Swisher, E. M.; Karlan, B. Y.; Agarwal, M. K.; Higgins, J.; Friedman, C.; Villegas, E.; Jacquemont, C.; Farrugia, D. J.; Couch, F. J.; Urban, N.; Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008, 1116-1120.
38. Sakai, W.; Swisher, E. M.; Jacquemont, C.; Chandramohan, K. V.; Couch, F. J.; Langdon, S. P.; Wurz, K.; Higgins, J.; Villegas, E.; Taniguchi, T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res., 2009, 69(16), 6381-6386.
39. Swisher, E. M.; Sakai, W.; Karlan, B. Y.; Wurz, K.; Urban, N.; Taniguchi, T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res., 2008, 68(8), 2581-2586.
40. Fong, P. C.; Yap, T. A.; Boss, D. S.; Carden, C. P.; Mergui-Roelvink, M.; Gourley, C.; Greve, J. D.; Lubinski, J.; Shanley, S.; Messiou, C.; A'Hern, R.; Tutt, A.; Ashworth, A.; Stone, J.; Carmichael, J.; Schellens, J. H. M.; deBono J. S.; Kaye, S. B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol., 2010, 28(15), 2512-2519.